Glugene Therapeutics (CEO Moon-soo Lee) is expanding its business based on its precision gene delivery (AAV) development technology. The company utilizes evolutionary design technology and AI to develop highly targeted AAV gene delivery vectors. The company was co-founded by CEO Moon-soo Lee, who has experience with KOSDAQ listings, and Professor Jae-hyung Jang of Yonsei University. Currently, Glugene Therapeutics has built a database of over 1 billion engineered vectors and is actively pursuing a co-development model with gene therapy developers. Notably, it has secured an AAV patent technology capable of delivering directly to pulmonary artery smooth muscle cells, significantly increasing the potential for commercialization into a therapeutic pipeline. Alongside process development and early-stage production services, the company plans to lower the high costs of gene therapies through its advanced precision delivery technology and secured productivity.
[2026 First Half Innovative Patent Technology Awards] Developing Gene Therapies Using AI
